Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

THE LIPOSOME COMPANY's ABELCET (ABLC) GAINS APPROVAL FOR ASPERGILLOSIS IN SIX MONTHS -- FIRM's FIRST DRUG IN THE U.S.; LAUNCH EXPECTED IN JANUARY

Executive Summary

The Liposome Company's amphotericin B lipid complex Abelcet (formerly called ABLC), was approved Nov. 20 by FDA for treatment of patients with the systemic fungal infection aspergillosis who are refractory to or intolerant of conventional amphotericin B therapy. The NDA was submitted May 24 and was given a priority review by FDA in just under six months.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel